Slaughter and May advised Thermo Fisher Scientific on its agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc

Slaughter and May advised Thermo Fisher Scientific on its agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc for approximately €90 million in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients. The transaction closed in September 2019 and the site will become part of Thermo Fisher's Pharma Services business within its Laboratory Products and Services Segment.